Anti-DLL3 antibodies and uses thereof
US12037391B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2019 |
| Grant date | Jul 16, 2024 |
| Priority date | — |
| Expiry date | Aug 13, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/705
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Anti-DLL3 antibodies and antigen-binding fragments thereof, anti-CD47 antibodies and antigen-binding fragments thereof, and anti-CD47/DLL3 bispecific antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases, such as cancer and/or associated complications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.